Am­i­cus’ lat­est pos­i­tive up­date on Pompe drug hints at ac­cel­er­at­ed ap­proval pitch

In the lat­est twist for what’s proved to be a year-long mar­ket thriller of dra­mat­ic ups and downs, Am­i­cus Ther­a­peu­tics CEO John Crow­ley to­day peeled the cov­ers off an up­dat­ed — and up­beat — look at how their drug ATB200/AT2221 per­formed in a Phase I/II study of Pompe dis­ease. And he’s hint­ing that the pos­i­tive re­sults could pave the way to an ac­cel­er­at­ed ap­proval — pro­vid­ed reg­u­la­tors are en­cour­ag­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER